中华骨质疏松和骨矿盐疾病杂志2024，Vol.17Issue(2)：176-181,6.DOI:10.3969/j.issn.1674-2591.2024.02.012
地舒单抗在骨质疏松初始、序贯、联合治疗等方面的临床研究进展
Progress in clinical research of denosumab in initial,sequential and combination therapy of osteoporosis
摘要
Abstract
Denosumab(DMAb)was the first human receptor activator of nuclear factor-κB(RANKL)antibody.Since its marketing in 2020 in China,DMAb has been widely used in osteoporosis treatment.As an important member of the antiresorptic drugs,its usage in initial,sequential and combined treatment of osteoporosis have also attracted a lot of attention.This article summarizes the latest clinical studies on the effects of different strategies of DMAb in osteoporosis treatment in recent years,so as to provide some references for its rational clinical application.关键词
地舒单抗/骨质疏松症/核因子-κB受体活化因子配Key words
denosumab/osteoporosis/receptor activator of nuclear factor-κB ligand分类
医药卫生引用本文复制引用
杨蕾,周广平,付勤,田野..地舒单抗在骨质疏松初始、序贯、联合治疗等方面的临床研究进展[J].中华骨质疏松和骨矿盐疾病杂志,2024,17(2):176-181,6.基金项目
国家自然科学基金(81970760) （81970760）
辽宁省应用基础研究计划(联合计划)(2022JH2/10500050) （联合计划）
辽宁省教育厅基本科研项目(LJKMZ20221164) （LJKMZ20221164）
中国医科大学附属盛京医院345人才工程(M1456) （M1456）
